Edition:
United States

Karyopharm Therapeutics Inc (KPTI.OQ)

KPTI.OQ on NASDAQ Stock Exchange Global Select Market

8.81USD
23 Jul 2019
Change (% chg)

$0.48 (+5.76%)
Prev Close
$8.33
Open
$9.02
Day's High
$9.15
Day's Low
$8.63
Volume
1,398,824
Avg. Vol
498,927
52-wk High
$21.69
52-wk Low
$3.93

Latest Key Developments (Source: Significant Developments)

Karyopharm Therapeutics - On July 2, Anand Varadan Resigned As Chief Commercial Officer, Effective July 5
Wednesday, 3 Jul 2019 02:49pm EDT 

July 3 (Reuters) - Karyopharm Therapeutics Inc ::KARYOPHARM THERAPEUTICS - ON JULY 2, ANAND VARADAN RESIGNED AS EXECUTIVE VICE PRESIDENT, CHIEF COMMERCIAL OFFICER, EFFECTIVE JULY 5.  Full Article

Karyopharm Announces FDA Approval Of Xpovio For Treatment Of Patients With Relapsed Or Refractory Multiple Myeloma
Wednesday, 3 Jul 2019 01:07pm EDT 

July 3 (Reuters) - Karyopharm Therapeutics Inc ::KARYOPHARM ANNOUNCES FDA APPROVAL OF XPOVIO™ (SELINEXOR) FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA.KARYOPHARM THERAPEUTICS - EXPECTS XPOVIO TO BECOME COMMERCIALLY AVAILABLE IN U.S. ON OR BEFORE JULY 10.  Full Article

FDA Approves New Treatment For Refractory Multiple Myeloma
Wednesday, 3 Jul 2019 12:51pm EDT 

July 3 (Reuters) - U.S. Food and Drug Administration::FDA APPROVES NEW TREATMENT FOR REFRACTORY MULTIPLE MYELOMA.U.S. FDA - GRANTED ACCELERATED APPROVAL TO XPOVIO TABLETS IN COMBINATION WITH CORTICOSTEROID DEXAMETHASONE FOR TREATMENT OF ADULT PATIENTS WITH RRMM.FDA - GRANTED APPROVAL OF XPOVIO TO KARYOPHARM THERAPEUTICS.  Full Article

Karyopharm Submits MAA To EMA For Selinexor For Treatment Of Patients With Penta-Refractory Multiple Myeloma
Tuesday, 8 Jan 2019 12:20pm EST 

Jan 8 (Reuters) - Karyopharm Therapeutics Inc ::KARYOPHARM ANNOUNCES SUBMISSION OF MARKETING AUTHORIZATION APPLICATION TO THE EUROPEAN MEDICINES AGENCY FOR SELINEXOR FOR THE TREATMENT OF PATIENTS WITH PENTA-REFRACTORY MULTIPLE MYELOMA.KARYOPHARM THERAPEUTICS - SELINEXOR MAA HAS BEEN GRANTED ACCELERATED ASSESSMENT BY EMA'S COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE.KARYOPHARM - NDA SEEKING ACCELERATED APPROVAL FOR ORAL SELINEXOR WITH LOW DOSE DEXAMETHASONE HAS AN ACTION DATE OF APRIL 6, 2019 UNDER PDUFA.  Full Article

Karyopharm Q3 Loss Per Share $0.79
Thursday, 8 Nov 2018 07:00am EST 

Nov 8 (Reuters) - Karyopharm Therapeutics Inc ::KARYOPHARM REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND HIGHLIGHTS RECENT COMPANY PROGRESS.Q3 LOSS PER SHARE $0.79.Q3 EARNINGS PER SHARE VIEW $-0.89 -- THOMSON REUTERS I/B/E/S.KARYOPHARM THERAPEUTICS - U.S. FDA ACCEPTS CO'S NEW DRUG APPLICATION FOR SELINEXOR AND GRANTS PRIORITY REVIEW; PDUFA ACTION DATE OF APRIL 6, 2019.FAST TRACK DESIGNATION RECEIVED FOR SELINEXOR IN RELAPSED OR REFRACTORY DLBCL.COMPLETED $172.5 MILLION CONVERTIBLE SENIOR NOTE OFFERING; CASH-ON-HAND EXPECTED TO FUND CO INTO 2Q 2020.KARYOPHARM THERAPEUTICS - TO SUBMIT MARKETING AUTHORIZATION APPLICATION TO EMA IN EARLY 2019 WITH A REQUEST FOR CONDITIONAL APPROVAL FOR SELINEXOR.  Full Article

Karyopharm Therapeutics Announces Management Change
Friday, 26 Oct 2018 07:00am EDT 

Oct 26 (Reuters) - Karyopharm Therapeutics Inc ::KARYOPHARM THERAPEUTICS ANNOUNCES MANAGEMENT CHANGE.KARYOPHARM THERAPEUTICS - MIKE FALVEY, EXECUTIVE VICE PRESIDENT, CHIEF FINANCIAL OFFICER AND TREASURER, INTENDS TO LEAVE CO TO PURSUE OTHER INTERESTS.KARYOPHARM THERAPEUTICS INC - EXECUTIVE SEARCH WILL COMMENCE IMMEDIATELY TO FILL FALVEY'S POSITION.KARYOPHARM THERAPEUTICS - FALVEY TO CONTINUE CURRENT RESPONSIBILITIES UNTIL SUCCESSOR NAMED TO ENSURE "NO DISRUPTION IN FINANCIAL LEADERSHIP OF CO".  Full Article

Karyopharm's Selinexor Achieves 26.2 Pct Overall Response Rate In Phase 2b Storm Study
Thursday, 13 Sep 2018 07:20pm EDT 

Sept 13 (Reuters) - Karyopharm Therapeutics Inc ::PHASE 2B STORM DATA EVALUATING SELINEXOR IN PATIENTS WITH PENTA-REFRACTORY MULTIPLE MYELOMA PRESENTED AT THE SOCIETY OF HEMATOLOGIC ONCOLOGY 2018 ANNUAL MEETING.KARYOPHARM THERAPEUTICS-ORAL SELINEXOR ACHIEVES 26.2% OVERALL RESPONSE RATE AND DURATION OF RESPONSE OF 4.4 MONTHS IN OVERALL STUDY POPULATION.COMMERCIAL PREPARATION UNDERWAY; NEW DRUG APPLICATION SUBMITTED TO FDA.  Full Article

Karyopharm Announces Positive Top-Line Data From Phase 2b STORM Study Evaluating Selinexor In Patients With Penta-Refractory Multiple Myeloma
Monday, 30 Apr 2018 04:05pm EDT 

April 30 (Reuters) - Karyopharm Therapeutics Inc ::KARYOPHARM ANNOUNCES POSITIVE TOP-LINE DATA FROM PHASE 2B STORM STUDY EVALUATING SELINEXOR IN PATIENTS WITH PENTA-REFRACTORY MULTIPLE MYELOMA.KARYOPHARM THERAPEUTICS INC - SELINEXOR CONTINUES TO DEMONSTRATE A PREDICTABLE AND MANAGEABLE TOLERABILITY PROFILE.KARYOPHARM THERAPEUTICS INC - COMPANY PLANS TO SUBMIT A NEW DRUG APPLICATION TO FDA IN SECOND HALF OF 2018.KARYOPHARM THERAPEUTICS INC - REGARDING STORM STUDY'S PRIMARY OBJECTIVE, ORAL SELINEXOR ACHIEVED A 25.4% OVERALL RESPONSE RATE.KARYOPHARM THERAPEUTICS INC - PLANS TO SUBMIT A MARKETING AUTHORIZATION APPLICATION TO EUROPEAN MEDICINES AGENCY IN EARLY 2019.KARYOPHARM THERAPEUTICS INC - EXPECTING TO COMPLETE ENROLLMENT IN BOSTON STUDY BY END OF 2018, WITH TOP-LINE DATA ANTICIPATED IN 2019.  Full Article

Karyopharm Therapeutics Reports Q4 Loss Per Share Of $0.80
Thursday, 15 Mar 2018 07:00am EDT 

March 15 (Reuters) - Karyopharm Therapeutics Inc ::KARYOPHARM REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND HIGHLIGHTS RECENT PROGRESS.Q4 LOSS PER SHARE $0.80.Q4 EARNINGS PER SHARE VIEW $-0.65 -- THOMSON REUTERS I/B/E/S.PHASE 2B STORM STUDY EVALUATING SELINEXOR IN PATIENTS WITH PENTA-REFRACTORY MYELOMA REMAINS ON TRACK.TOP-LINE DATA FROM PHASE 2B STORM STUDY EXPECTED END OF APRIL 2018.KARYOPHARM - CASH, CASH EQUIVALENTS AND INVESTMENTS AS OF DEC 31, 2017, INCLUDING RESTRICTED CASH, TOTALED $176.4 MILLION, VERSUS $175.5 MILLION AT DEC 31, 2016.EXPECTS EXISTING CASH, CASH EQUIVALENTS AND INVESTMENTS TO BE SUFFICIENT TO FUND OPERATIONS THROUGH AT LEAST Q1 2019.QTRLY LICENSE AND OTHER REVENUE $1.5 MILLION VERSUS $ 47,000.  Full Article

Karyopharm Announces Agreement For Biogen To Acquire KPT-350
Thursday, 25 Jan 2018 06:30am EST 

Jan 25 (Reuters) - Karyopharm Therapeutics Inc ::KARYOPHARM ANNOUNCES AGREEMENT FOR BIOGEN TO ACQUIRE KPT-350 FOR THE TREATMENT OF NEUROLOGICAL AND NEURODEGENERATIVE CONDITIONS.KARYOPHARM THERAPEUTICS INC - DEAL VALUED AT UP TO $217 MILLION.KARYOPHARM THERAPEUTICS - ‍BIOGEN IS ACQUIRING KPT-350 AND OTHER ASSETS TARGETING CERTAIN NEUROLOGICAL CONDITIONS, INCLUDING ALS.KARYOPHARM - DEAL INCLUDES $10 MILLION UPFRONT PAYMENT TO KARYOPHARM, AND POTENTIAL $207 MILLION IN FUTURE MILESTONES, PLUS ROYALTIES.KARYOPHARM - CO ALSO ELIGIBLE TO GET TIERED ROYALTIES FROM BIOGEN THAT REACH LOW DOUBLE DIGITS BASED ON FUTURE NET SALES OF SOME PRODUCT CANDIDATES.  Full Article

Karyopharm Therapeutics prices blood cancer treatment after FDA approval

Karyopharm Therapeutics Inc on Wednesday set a list-price for its blood cancer treatment Xpovio at $22,000 per month, following accelerated approval from the U.S. Food and Drug Administration.